Tower Research Capital LLC (Trc) Eye Point Pharmaceuticals, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,235 shares of EYPT stock, worth $14,634. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,235
Previous 8,700
85.8%
Holding current value
$14,634
Previous $81,000
79.01%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding EYPT
# of Institutions
167Shares Held
68MCall Options Held
421KPut Options Held
401K-
Cormorant Asset Management, LP Boston, MA8.33MShares$98.7 Million18.35% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.19MShares$73.4 Million2.57% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.56MShares$65.9 Million0.13% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.42MShares$52.3 Million0.12% of portfolio
-
Franklin Resources Inc San Mateo, CA4.17MShares$49.4 Million0.02% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $404M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...